McClellan takes to the airways
During a Jan. 15 appearance on National Public Radio's "Diane Rehm Show," Commissioner McClellan responded to questions about pressure from Congress to speed up approval times: "We do get pressure from Congress and other constituents...[but] I think we've got some win-win opportunities here." McClellan cited the additional resources and authorities afforded to the agency through the reauthorization of the Prescription Drug User Fee Act and noted that FDA will be expanding its staff for reviewing medical treatments and devices...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”